Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:300049'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.76 Med: 10.18 Max: 14.36
Current: 14.36
During the past 13 years, Inner Mongolia Furui Medical Science Co's highest Return-on-Tangible-Equity was 14.36%. The lowest was 3.76%. And the median was 10.18%.
SZSE:300049's Return-on-Tangible-Equity is ranked better than 87.81% of 1206
companies
in the Biotechnology industry
Industry Median: -42.15
vs SZSE:300049: 14.36
Inner Mongolia Furui Medical Science Co (SZSE:300049) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Inner Mongolia Furui Medical Science Co Return-on-Tangible-Equity Related Terms
Inner Mongolia Furui Medical Science Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inner Mongolia Furui Medical Science Co Return-on-Tangible-Equity Chart
Inner Mongolia Furui Medical Science Co Annual Data
SZSE:300049 vs VRTX, REGN, MRNA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Inner Mongolia Furui Medical Science Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inner Mongolia Furui Medical Science Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inner Mongolia Furui Medical Science Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Inner Mongolia Furui Medical Science Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.63% mean?
Inner Mongolia Furui Medical Science Co (SZSE:300049) has a Return-on-Tangible-Equity of 10.63% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Inner Mongolia Furui Medical Science Co and its competitors. This is near median its historical median of 10.18. Over the past decade, Inner Mongolia Furui Medical Science Co's Return-on-Tangible-Equity has ranged from 3.76 to 14.36. According to the industry distribution chart, Inner Mongolia Furui Medical Science Co ranks #147 out of 1206 companies in the Biotechnology industry, placing it in the top 12.2%.
Is Inner Mongolia Furui Medical Science Co's Return-on-Tangible-Equity too high?
Inner Mongolia Furui Medical Science Co's current Return-on-Tangible-Equity of 10.63% is near median its 10-year median of 10.18. Over the past 10 years, this metric has ranged from a low of 3.76 to a high of 14.36. Based on the distribution chart, Inner Mongolia Furui Medical Science Co ranks #147 out of 1206 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inner Mongolia Furui Medical Science Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Inner Mongolia Furui Medical Science Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inner Mongolia Furui Medical Science Co ranks #147 out of 1206 companies for Return-on-Tangible-Equity. This places Inner Mongolia Furui Medical Science Co in the top 12% of its industry — outperforming the majority of peers. Historically, Inner Mongolia Furui Medical Science Co's own Return-on-Tangible-Equity has ranged from 3.76 to 14.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Inner Mongolia Furui Medical Science Co and its competitors. Inner Mongolia Furui Medical Science Co's current Return-on-Tangible-Equity is 10.63%, which is near median its own 10-year median of 10.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inner Mongolia Furui Medical Science Co stock overvalued right now?
Based on GuruFocus' analysis, Inner Mongolia Furui Medical Science Co (SZSE:300049) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥63.30, compared to a current price of ¥44.97 — trading 29% below its estimated fair value. The current Return-on-Tangible-Equity is 10.63%, which is near median its 10-year median of 10.18. Inner Mongolia Furui Medical Science Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Inner Mongolia Furui Medical Science Co (SZSE:300049), the current Return-on-Tangible-Equity is 10.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inner Mongolia Furui Medical Science Co (SZSE:300049) Overvalued in 2026?
Based on GuruFocus' analysis, Inner Mongolia Furui Medical Science Co stock appears to be undervalued.
The current stock price of ¥44.97 is trading 29% below its estimated GF Value™ of ¥63.30.
GuruFocus considers Inner Mongolia Furui Medical Science Co to be Modestly Undervalued.
Key valuation signals for SZSE:300049:
Return-on-Tangible-Equity: 10.63% (near median its 10-year median of 10.18)
GF Value™: ¥63.30 vs. price of ¥44.97 (29% below fair value)
No single metric tells the full story. See the SZSE:300049 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inner Mongolia Furui Medical Science Co Ltd is a China based medical service platform company. It provides disease diagnosis, drug treatment and chronic disease management centered on the liver disease field. The product portfolio of the company includes tablets, capsules, and plaster. In addition, the company is also engaged in providing health-care services.
80GF Score
Get the complete analysis for SZSE:300049
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300049 has been successfully added to your 
